Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis

International Journal of Oncology

Volumn 29, Issue 2, 2006, Pages 357-364

  Shinji, Seiichi ^a   Naito, Zenya ^a   Ishiwata, Toshiyuki ^a   Tanaka, Noritake ^a   Furukawa, Kiyonori ^a   Suzuki, Hideyuki ^a   Seya, Tomoko ^a   Kan, Hayato ^a   Tsuruta, Hiroyuki ^a   Matsumoto, Satoshi ^a   Matsuda, Akihisa ^a   Teranishi, Nobuhisa ^a   Ohaki, Yoshiharu ^a   Tajiri, Takashi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Colorectal carcinoma; Microvessel density; Neuroendocrine; Poorly differentiated adenocarcinoma; Vascular endothelial growth factor

Indexed keywords

CD34 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2 40; MONOCLONAL ANTIBODY D2-40;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOSYNTHESIS; CARCINOMA; CELL DIFFERENTIATION; CHEMISTRY; COLORECTAL TUMOR; FEMALE; HUMAN; LIVER TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; CARCINOMA, NEUROENDOCRINE; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 33747611561     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.2.357     Document Type: Article

References (49)

1. Taniyama K, Suzuki H, Matsumoto M, Hakamada K, Toyama K and Tahara E: Flow cytometric DNA analysis of poorly differentiated adenocarcinoma of the colorectum. Jpn J Clin Oncol 21: 406-411, 1991.
2. Cass AW, Million RR and Pfaff WW: Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer 37: 2861-2865, 1976.
3. Copeland EM, Miller LD and Jones RS: Prognostic factors in carcinoma of the colon and rectum. Am J Surg 116: 875-881, 1968.
4. Chung CK, Zaino RJ and Stryker JA: Colorectal carcinoma: evaluation of histologic grade and factors influencing prognosis. J Surg Oncol 21: 143-148, 1982. (Pubitemid 13250510)
5. Kulke MH and Mayer RJ: Carcinoid tumors. N Engl J Med 340: 858-868, 1999.
6. Shinji S, Tajiri T, Ishiwata T, Seya T, Tanaka N and Naito Z: Different expression levels of lumican in human carcinoid tumor and neuroendocrine cell carcinoma. Int J Oncol 26: 873-880, 2005.
7. Staren ED, Gould VE, Jansson DS, Hyser M, Gooch GT and Economou SG: Neuroendocrine differentiation in 'poorly differentiated' colon carcinomas. Am Surg 56: 412-419, 1990.
8. Gaffey MJ, Mills SE and Lack EE: Neuroendocrine carcinoma of the colon and rectum. A clinicopathologic, ultrastructural, and immunohistochemical study of 24 cases. Am J Surg Pathol 14: 1010-1023, 1990. (Pubitemid 20360707)
9. Saclarides TJ, Szeluga D and Staren ED: Neuroendocrine cancers of the colon and rectum. Results of a ten-year experience. Dis Colon Rectum 37: 635-642, 1994.
10. Grabowski P, Schindler I, Anagnostopoulos I, et al: Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer. Eur J Gastroenterol Hepatol 13: 405-411, 2001. (Pubitemid 32319908)
11. Moertel CG, Kvols LK, O'Connell MJ and Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227-232, 1991.
12. Dor Y, Porat R and Keshet E: Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 280: C1367-C1374, 2001. (Pubitemid 32553191)
13. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997. (Pubitemid 27076453)
14. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999. (Pubitemid 29038270)
15. Becker C, Fantini MC, Schramm C, et al: TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21: 491-501, 2004. (Pubitemid 39370505)
16. Reinmuth N, Fan F, Liu W, et al: Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 82: 1377-1389, 2002. (Pubitemid 35191541)
17. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964-3968, 1995.
18. Takahashi Y, Bucana CD, Cleary KR and Ellis LM: p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 79: 34-38, 1998. (Pubitemid 28157723)
19. Tokunaga T, Oshika Y, Abe Y, et al: Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77: 998-1002, 1998. (Pubitemid 28101792)
20. Ishigami SI, Arii S, Furutani M, et al: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 78: 1379-1384, 1998. (Pubitemid 28495254)
21. Takahashi Y, Tucker SL, Kitadai Y, et al: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132: 541-546, 1997. (Pubitemid 27215097)
22. Grabowski P, Schonfelder J, Ahnert-Hilger G, et al: Expression of neuroendocrine markers: a signature of human undifferentiated carcinoma of the colon and rectum. Virchows Arch 441: 256-263, 2002.
23. Vermeulen PB, Gasparini G, Fox SB, et al: Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A: 2474-2484, 1996. (Pubitemid 27080786)
24. Kahn HJ and Marks A: A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 82: 1255-1257, 2002.
25. Kahn HJ, Bailey D and Marks A: Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 15: 434-440, 2002. (Pubitemid 34326952)
26. Inoue K, Ozeki Y, Suganuma T, Sugiura Y and Tanaka S: Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 79: 206-213, 1997.
27. Ishiwata T: Immunohistochemical and in situ hybridization analysis of lumican in colorectal carcinoma. Burlington: Elsevier Academic Press, 2005.
28. Ishiwata T, Kornmann M, Beger HG and Korc M: Enhanced fibroblast growth factor 5 expression in stromal and exocrine elements of the pancreas in chronic pancreatitis. Gut 43: 134-139, 1998. (Pubitemid 28335502)
29. Kubo T and Watanabe H: Neoplastic argentaffin cells in gastric and intestinal carcinomas. Cancer 27: 447-454, 1971.
30. Smith DM Jr and Haggitt RC: The prevalence and prognostic significance of argyrophil cells in colorectal carcinomas. Am J Surg Pathol 8: 123-128, 1984.
31. Staren ED, Gould VE, Warren WH, et al: Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation. Surgery 104: 1080-1089, 1988. (Pubitemid 19011989)
32. Jansson D, Gould VE, Gooch GT, et al: Immunohistochemical analysis of colon carcinomas applying exocrine and neuroendocrine markers. APMIS 96: 1129-1139, 1988. (Pubitemid 19037928)
33. Lewin KJ: The endocrine cells of the gastrointestinal tract. The normal endocrine cells and their hyperplasias. Part I. Pathol Annu 21: 1-27, 1986.
34. Yaziji H and Broghamer WL Jr: Primary small cell undifferentiated carcinoma of the rectum associated with ulcerative colitis. South Med J 89: 921-924, 1996. (Pubitemid 26295291)
35. Thomas RM and Sobin LH: Gastrointestinal cancer. Cancer 75: 154-170, 1995.
36. DiSario JA, Burt RW, Kendrick ML and McWhorter WP: Colorectal cancers of rare histologic types compared with adenocarcinomas. Dis Colon Rectum 37: 1277-1280, 1994.
37. Johnson LR: Regulation of gastrointestinal mucosal growth. Physiol Rev 68: 456-502, 1988.
38. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
39. Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989. (Pubitemid 19115892)
40. Rak J, Filmus J and Kerbel RS: Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer 32A: 2438-2450, 1996.
41. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
42. Keck PJ, Hauser SD, Krivi G, et al: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309-1312, 1989. (Pubitemid 20066717)
43. Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989. (Pubitemid 20066716)
44. Plouet J, Schilling J and Gospodarowicz D: Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 8: 3801-3806, 1989. (Pubitemid 20016061)
45. Cascinu S, Staccioli MP, Gasparini G, et al: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 6: 2803-2807, 2000. (Pubitemid 30482120)
46. Warren RS, Yuan H, Matli MR, Gillett NA and Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95: 1789-1797, 1995.
47. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65, 2003.
48. Ferrara N, Hillan KJ and Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333: 328-335, 2005. (Pubitemid 40848295)
49. Glade-Bender J, Kandel JJ and Yamashiro DJ: VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 3: 263-276, 2003. (Pubitemid 36458758)